Foghorn therapeutics to host virtual investor event to review pipeline updates in conjunction with 2025 aacr annual meeting

Company to share new preclinical combination data for fhd-909 (ly4050784), a potential first-in-class selective smarca2 inhibitor, with non-small cell lung cancer (nsclc) as the primary target population

FHTX Ratings Summary

FHTX Quant Ranking